BTA-106

N/A

Report date: 2025/01/26 16:15:45

Base Information

Drug NameBTA-106

Drug Alias Nameanti-IgM/HLA-DR bispecific antibody (Zenyaku Kogyo)BTA-106

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionHistocompatibility antigens class II modulatorsImmunoglobulin M modulators

TargetsHistocompatibility antigens class IIImmunoglobulin M

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesZenyaku Kogyo Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesZenyaku Kogyo Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A